Brief: Mustang Bio Announces Publication Of Data From Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells In High-Grade Glioma
07/03/2024 12:50
March 7 (Reuters) - Mustang Bio:
* MUSTANG BIO ANNOUNCES PUBLICATION IN NATURE MEDICINE OF
DATA
FROM PHASE 1 TRIAL EVALUATING MB-101 IL13RΑ2-TARGETED CAR
T-CELLS IN HIGH-GRADE GLIOMA
* MUSTANG BIO INC - MB-101 WAS WELL-TOLERATED
Source text for Eikon: ID:nGNXHwdy6
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie